{"description":"All adverse events were recorded on the adverse event case report/worksheet by the principal investigator and/or research team, as well as evaluated by a qualified physician","eventGroups":[{"deathsNumAffected":1,"deathsNumAtRisk":13,"description":"Pembrolizumab 200 mg, 30 minute IV infusion every 21 days up to 24 cycles if equal or higher than minor response and without serious adverse events after 8 cycles","id":"EG000","otherNumAffected":13,"otherNumAtRisk":13,"seriousNumAffected":3,"seriousNumAtRisk":13,"title":"Single Arm, Intermediate-high Risk SMM Participants"}],"frequencyThreshold":"0","otherEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Renal and urinary disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":13}],"term":"Acute kidney injury"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":13}],"term":"Alanine aminotranferase increased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}],"term":"Allergic rhinitis"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}],"term":"Alopecia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":13}],"term":"Anemia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}],"term":"Anorexia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":13}],"term":"Aspartate aminotransferase increased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Cardiac disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}],"term":"Atrial fibrillation"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Immune system disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}],"term":"Autoimmune disorder"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":13}],"term":"Back pain"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Eye disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}],"term":"Blurred vision"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}],"term":"Bronchial infection"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}],"term":"Chills"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":13}],"term":"Constipation"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":13}],"term":"Cough"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}],"term":"Creatinine increased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":13}],"term":"Diarrhea"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":13}],"term":"Dizziness"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Eye disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":13}],"term":"Dry eye"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}],"term":"Dyspepsia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":13}],"term":"Edema limbs"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Endocrine disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":13}],"term":"Endocrine disorders - Other, specify"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}],"term":"Epistaxis"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Eye disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}],"term":"Eye disorders - Other, specify"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Eye disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}],"term":"Eye pain"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":13}],"term":"Fatigue"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}],"term":"Fever"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}],"term":"Gastrointestinal disorders - Other, specify"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}],"term":"General disorders and administration site conditions - Other, specify"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}],"term":"Generalized muscle weakness"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}],"term":"Headache"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Renal and urinary disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}],"term":"Hematuria"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}],"term":"Hemorrhoids"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}],"term":"Hepatobiliary disorders - Other, specify"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":13}],"term":"Hot flashes"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}],"term":"Hypercalcemia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":13}],"term":"Hyperglycemia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}],"term":"Hyperuricemia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":13}],"term":"Hypocalcemia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":13}],"term":"Hypomagnesemia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}],"term":"Hyponatremia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":13}],"term":"Hypophosphatemia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":13}],"term":"Insomnia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":13}],"term":"Lipase increased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}],"term":"Memory impairment"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":13}],"term":"Metabolism and nutrition - Other, specify"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":13}],"term":"Mucositis oral"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":13}],"term":"Muscoloeskeletal and connective tissue disorder - Other, specify"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":13}],"term":"Myalgia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":13}],"term":"Nasal congestion"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":13}],"term":"Nausea"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}],"term":"Neck edema"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":13}],"term":"Neck pain"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}],"term":"Neoplasm benign, malignant and unspecified (incl cyst and polyps) - Other, specify"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}],"term":"Neutrophil count decreased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":13}],"term":"Pain"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Cardiac disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}],"term":"Palpitations"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":13}],"term":"Peripheral sensory neuropathy"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Eye disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}],"term":"Photophobia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}],"term":"Platelet count decreased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}],"term":"Prostate infection"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":13}],"term":"Pruritus"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Psychiatric disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}],"term":"Psychiatric disorders - Other, specify"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":13}],"term":"Rash maculo-papular"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Renal and urinary disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":13}],"term":"Renal and urinary disorders - Other, specify"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}],"term":"Respiratory, thoracic and mediastinal disorders - Other, specify"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":13}],"term":"Serum amylase increased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":13}],"term":"Skin and subcutaneous tissue disorders - Other, specify"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}],"term":"Tinnutis"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Hepatobiliary disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}],"term":"Transaminitis"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}],"term":"Tremor"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":13}],"term":"Upper respiratory infection"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Renal and urinary disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":13}],"term":"Urinary frequency"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Renal and urinary disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}],"term":"Urinary tract infection"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Renal and urinary disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}],"term":"Urinary tract pain"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Renal and urinary disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}],"term":"Urinary urgency"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}],"term":"Vomiting"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":13}],"term":"Weight loss"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}],"term":"Wheezing"}],"seriousEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"All adverse events were recorded on the adverse event case report/worksheet by the principal investigator and/or research team, as well as evaluated by a qualified physician","organSystem":"Hepatobiliary disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}],"term":"Transaminitis"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Renal and urinary disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}],"term":"Acute kidney injury"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE version 4.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13}],"term":"Myalgia"}],"timeFrame":"From time the consent form is signed through 90 days following cessation of treatment and at each examination on the Adverse Event case report/forms/worksheet, up to 2 years and 6 months"}